The positron emission tomography (pet) radiotracer market size has grown strongly in recent years. It will grow from $2.54 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing cancer diagnosis rates, expansion of nuclear medicine facilities, established use of fdg-based imaging, availability of cyclotron infrastructure, growth of diagnostic imaging services.
The positron emission tomography (pet) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in radiopharmaceutical R&D, expansion of theranostics applications, growing adoption of pet imaging in neurology and cardiology, increasing regulatory approvals for new tracers. Major trends in the forecast period include increasing development of target-specific radiotracers, rising adoption of pet imaging in oncology diagnostics, growing use of novel isotopes beyond fdg, expansion of personalized nuclear medicine applications, enhanced focus on short-half-life radiotracer production.
The rising prevalence of infectious diseases is expected to drive the growth of the positron emission tomography (PET) radiotracer market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. The increasing occurrence of these diseases is attributed to factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which contribute to the spread of pathogens. PET radiotracers support the management of infectious diseases by enabling visualization of metabolic activity and inflammation, facilitating infection detection, evaluation of treatment response, and differentiation between infectious and non-infectious conditions, thereby improving patient outcomes. For example, in February 2024, a report published by the UK Health Security Agency, a UK-based government organization, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 cases in 2022. Consequently, the growing burden of infectious diseases is contributing to the expansion of the PET radiotracer market.
Companies active in the positron emission tomography (PET) radiotracer market are increasingly focusing on the development of advanced diagnostic solutions, including PET imaging agents, to improve cancer detection and patient outcomes. PET imaging agents are radioactive substances used to visualize and quantify biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also referred to as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This prostate cancer imaging agent is designed to detect metastatic prostate cancer and supports physicians in identifying metastatic disease and guiding patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in individuals with suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels.
In February 2023, Lantheus Holdings Inc., a US-based developer of diagnostic products, acquired Cerveau Technologies for an undisclosed amount. This acquisition is intended to strengthen Lantheus Holdings’ imaging pipeline, particularly in the area of Alzheimer’s disease diagnostics, by integrating Cerveau’s MK-6240, a second-generation PET imaging agent that targets tau tangles in the brain. Cerveau Technologies Inc. is a US-based company involved in the development of positron emission tomography (PET) radiotracers.
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging.
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the positron emission tomography (pet) radiotracer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the PET radiotracer market by increasing costs of imported radioisotopes, synthesis modules, cyclotron components, and quality control equipment. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported isotopes and production technologies, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing operational expenses and affecting tracer availability. However, they are also encouraging domestic isotope production, regional radiopharmacy expansion, and localized supply chain development.
The positron emission tomography (pet) radiotracer market research report is one of a series of new reports that provides positron emission tomography (pet) radiotracer market statistics, including positron emission tomography (pet) radiotracer industry global market size, regional shares, competitors with a positron emission tomography (pet) radiotracer market share, detailed positron emission tomography (pet) radiotracer market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (pet) radiotracer industry. This positron emission tomography (pet) radiotracer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A positron emission tomography (PET) radiotracer is a radioactive substance used in PET imaging. This radiotracer is administered to a patient via injection, where it binds to specific biological targets, enabling the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders.
The primary types of PET radiotracers include F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and others. F-18 (Fluorodeoxyglucose 18) radiotracers are radioactive glucose analogs utilized in PET imaging to evaluate metabolic activity in tissues, particularly for cancer detection. These radiotracers are applied across various medical fields, including oncology, cardiology, gastrointestinal disorders, endocrine issues, and neurology. They are used by end-users such as hospitals and diagnostic centers, among others.
The positron emission tomography (PET) radiotracer market consists of sales of FDG (fluorodeoxyglucose), f-dopa (fluorodopa), C-11 methionine, C-11 methionine, F-18 naf (sodium fluoride), and C-11 choline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The positron emission tomography (pet) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in radiopharmaceutical R&D, expansion of theranostics applications, growing adoption of pet imaging in neurology and cardiology, increasing regulatory approvals for new tracers. Major trends in the forecast period include increasing development of target-specific radiotracers, rising adoption of pet imaging in oncology diagnostics, growing use of novel isotopes beyond fdg, expansion of personalized nuclear medicine applications, enhanced focus on short-half-life radiotracer production.
The rising prevalence of infectious diseases is expected to drive the growth of the positron emission tomography (PET) radiotracer market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. The increasing occurrence of these diseases is attributed to factors such as climate change, urbanization, globalization, antibiotic resistance, and shifts in human behavior, all of which contribute to the spread of pathogens. PET radiotracers support the management of infectious diseases by enabling visualization of metabolic activity and inflammation, facilitating infection detection, evaluation of treatment response, and differentiation between infectious and non-infectious conditions, thereby improving patient outcomes. For example, in February 2024, a report published by the UK Health Security Agency, a UK-based government organization, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 cases in 2022. Consequently, the growing burden of infectious diseases is contributing to the expansion of the PET radiotracer market.
Companies active in the positron emission tomography (PET) radiotracer market are increasingly focusing on the development of advanced diagnostic solutions, including PET imaging agents, to improve cancer detection and patient outcomes. PET imaging agents are radioactive substances used to visualize and quantify biological processes within the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also referred to as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada. This prostate cancer imaging agent is designed to detect metastatic prostate cancer and supports physicians in identifying metastatic disease and guiding patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in individuals with suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels.
In February 2023, Lantheus Holdings Inc., a US-based developer of diagnostic products, acquired Cerveau Technologies for an undisclosed amount. This acquisition is intended to strengthen Lantheus Holdings’ imaging pipeline, particularly in the area of Alzheimer’s disease diagnostics, by integrating Cerveau’s MK-6240, a second-generation PET imaging agent that targets tau tangles in the brain. Cerveau Technologies Inc. is a US-based company involved in the development of positron emission tomography (PET) radiotracers.
Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging.
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) radiotracer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the positron emission tomography (pet) radiotracer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the PET radiotracer market by increasing costs of imported radioisotopes, synthesis modules, cyclotron components, and quality control equipment. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported isotopes and production technologies, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing operational expenses and affecting tracer availability. However, they are also encouraging domestic isotope production, regional radiopharmacy expansion, and localized supply chain development.
The positron emission tomography (pet) radiotracer market research report is one of a series of new reports that provides positron emission tomography (pet) radiotracer market statistics, including positron emission tomography (pet) radiotracer industry global market size, regional shares, competitors with a positron emission tomography (pet) radiotracer market share, detailed positron emission tomography (pet) radiotracer market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (pet) radiotracer industry. This positron emission tomography (pet) radiotracer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A positron emission tomography (PET) radiotracer is a radioactive substance used in PET imaging. This radiotracer is administered to a patient via injection, where it binds to specific biological targets, enabling the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders.
The primary types of PET radiotracers include F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and others. F-18 (Fluorodeoxyglucose 18) radiotracers are radioactive glucose analogs utilized in PET imaging to evaluate metabolic activity in tissues, particularly for cancer detection. These radiotracers are applied across various medical fields, including oncology, cardiology, gastrointestinal disorders, endocrine issues, and neurology. They are used by end-users such as hospitals and diagnostic centers, among others.
The positron emission tomography (PET) radiotracer market consists of sales of FDG (fluorodeoxyglucose), f-dopa (fluorodopa), C-11 methionine, C-11 methionine, F-18 naf (sodium fluoride), and C-11 choline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Positron Emission Tomography (PET) Radiotracer Market Characteristics
3. Positron Emission Tomography (PET) Radiotracer Market Supply Chain Analysis
4. Global Positron Emission Tomography (PET) Radiotracer Market Trends and Strategies
5. Positron Emission Tomography (PET) Radiotracer Market Analysis of End Use Industries
7. Global Positron Emission Tomography (PET) Radiotracer Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Positron Emission Tomography (PET) Radiotracer Total Addressable Market (TAM) Analysis for the Market
9. Positron Emission Tomography (PET) Radiotracer Market Segmentation
10. Positron Emission Tomography (PET) Radiotracer Market Regional and Country Analysis
11. Asia-Pacific Positron Emission Tomography (PET) Radiotracer Market
12. China Positron Emission Tomography (PET) Radiotracer Market
13. India Positron Emission Tomography (PET) Radiotracer Market
14. Japan Positron Emission Tomography (PET) Radiotracer Market
15. Australia Positron Emission Tomography (PET) Radiotracer Market
16. Indonesia Positron Emission Tomography (PET) Radiotracer Market
17. South Korea Positron Emission Tomography (PET) Radiotracer Market
18. Taiwan Positron Emission Tomography (PET) Radiotracer Market
19. South East Asia Positron Emission Tomography (PET) Radiotracer Market
20. Western Europe Positron Emission Tomography (PET) Radiotracer Market
21. UK Positron Emission Tomography (PET) Radiotracer Market
22. Germany Positron Emission Tomography (PET) Radiotracer Market
23. France Positron Emission Tomography (PET) Radiotracer Market
24. Italy Positron Emission Tomography (PET) Radiotracer Market
25. Spain Positron Emission Tomography (PET) Radiotracer Market
26. Eastern Europe Positron Emission Tomography (PET) Radiotracer Market
27. Russia Positron Emission Tomography (PET) Radiotracer Market
28. North America Positron Emission Tomography (PET) Radiotracer Market
29. USA Positron Emission Tomography (PET) Radiotracer Market
30. Canada Positron Emission Tomography (PET) Radiotracer Market
31. South America Positron Emission Tomography (PET) Radiotracer Market
32. Brazil Positron Emission Tomography (PET) Radiotracer Market
33. Middle East Positron Emission Tomography (PET) Radiotracer Market
34. Africa Positron Emission Tomography (PET) Radiotracer Market
36. Positron Emission Tomography (PET) Radiotracer Market Competitive Landscape and Company Profiles
37. Positron Emission Tomography (PET) Radiotracer Market Other Major and Innovative Companies
40. Positron Emission Tomography (PET) Radiotracer Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Positron Emission Tomography (PET) Radiotracer Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses positron emission tomography (pet) radiotracer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for positron emission tomography (pet) radiotracer? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The positron emission tomography (pet) radiotracer market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18); Ga-68 (Fibroblast Activation Protein Inhibitor); Other Radiotracer Types2) By Application: Cancer; Heart Disease; Gastrointestinal; Endocrine; Neurological Disorders; Other Applications
3) By End-User: Hospitals; Diagnostic Centers; Other End-Users
Subsegments:
1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose); F-18 Fluoroethyltyrosine (FET); F-18 Florbetapir (Amyloid PET Imaging)2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging); Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging); Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging)
3) By Other Radiotracer Types: C-11 (Carbon-11); N-13 (Nitrogen-13); O-15 (Oxygen-15); Rb-82 (Rubidium-82); I-124 (Iodine-124)
Companies Mentioned: Cardinal Health Inc.; GE Healthcare Technologies Inc.; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Jubilant Pharma Limited; SOFIE Biosciences; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Nordion Inc.; Isologic Innovative Radiopharmaceuticals; ABX Advanced Biochemical Compounds GmbH; IBA Radiopharma Solutions S.A.; ImaginAb Inc.; Radiomedix Inc.; Curium Pharma; Blue Earth Diagnostics Ltd.; Eckert & Ziegler Radiopharma GmbH; Advanced Accelerator Applications (Novartis); Telix Pharmaceuticals Limited; PETNET Solutions Inc.; Piramal Imaging
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Positron Emission Tomography (PET) Radiotracer market report include:- Cardinal Health Inc.
- GE Healthcare Technologies Inc.
- Bracco Imaging S.p.A.
- Lantheus Holdings Inc.
- Jubilant Pharma Limited
- SOFIE Biosciences
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
- Nordion Inc.
- Isologic Innovative Radiopharmaceuticals
- ABX Advanced Biochemical Compounds GmbH
- IBA Radiopharma Solutions S.A.
- ImaginAb Inc.
- Radiomedix Inc.
- Curium Pharma
- Blue Earth Diagnostics Ltd.
- Eckert & Ziegler Radiopharma GmbH
- Advanced Accelerator Applications (Novartis)
- Telix Pharmaceuticals Limited
- PETNET Solutions Inc.
- Piramal Imaging
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.78 Billion |
| Forecasted Market Value ( USD | $ 3.95 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
